ClinicalTrials.gov
History of Changes for Study: NCT03522246
A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy (ATHENA)
Latest version (submitted September 14, 2023) on ClinicalTrials.gov
  • A study version is represented by a row in the table.
  • Select two study versions to compare. One each from columns A and B.
  • Choose either the "Merged" or "Side-by-Side" comparison format to specify how the two study versions are to be displayed. The Side-by-Side format only applies to the Protocol section of the study.
  • Click "Compare" to do the comparison and show the differences.
  • Select a version's Submitted Date link to see a rendering of the study for that version.
  • The yellow A/B choices in the table indicate the study versions currently compared below. A yellow table row indicates the study version currently being viewed.
  • Hover over the "Recruitment Status" to see how the study's recruitment status changed.
  • Study edits or deletions are displayed in red.
  • Study additions are displayed in green.
Study Record Versions
Version A B Submitted Date Changes
1 April 30, 2018 None (earliest Version on record)
2 June 26, 2018 Recruitment Status, Study Status, Contacts/Locations, Outcome Measures and Oversight
3 October 9, 2018 Contacts/Locations, Study Status and Conditions
4 November 6, 2018 Study Status and Contacts/Locations
5 December 20, 2018 Study Status and Contacts/Locations
6 February 5, 2019 Study Status and Contacts/Locations
7 March 1, 2019 Study Status and Contacts/Locations
8 April 11, 2019 Study Status and Contacts/Locations
9 April 15, 2019 Contacts/Locations and Study Status
10 April 29, 2019 Contacts/Locations and Study Status
11 July 31, 2019 Study Status and Contacts/Locations
12 October 29, 2020 Recruitment Status, Contacts/Locations, Study Status, Eligibility and Study Design
13 July 2, 2021 Contacts/Locations and Study Status
14 November 3, 2021 Study Status and Contacts/Locations
15 February 17, 2023 Study Status and Contacts/Locations
16 June 7, 2023 Sponsor/Collaborators, Study Status and Study Identification
17 June 12, 2023 Study Status and Study Identification
18 September 14, 2023 Study Status and Contacts/Locations
Comparison Format:
Scroll up to access the controls
Study NCT03522246
Submitted Date:  September 14, 2023 (v18)
Open or close this module Study Identification
Unique Protocol ID: CO-338-087/GOG-3020/ENGOT-ov45
Brief Title: A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy (ATHENA)
Official Title: ATHENA (A Multicenter, Randomized, Double-Blind, Placebo- Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy)
Secondary IDs: 2017-004557-17 [EudraCT Number]
Open or close this module Study Status
Record Verification: September 2023
Overall Status: Active, not recruiting
Study Start: May 14, 2018
Primary Completion: December 30, 2024 [Anticipated]
Study Completion: December 30, 2030 [Anticipated]
First Submitted: April 9, 2018
First Submitted that
Met QC Criteria:		 April 30, 2018
First Posted: May 11, 2018 [Actual]
Last Update Submitted that
Met QC Criteria:		 September 14, 2023
Last Update Posted: September 15, 2023 [Actual]
Open or close this module Sponsor/Collaborators
Sponsor: pharmaand GmbH
Responsible Party: Sponsor
Collaborators: Bristol-Myers Squibb
Gynecologic Oncology Group
European Network of Gynaecological Oncological Trial Groups (ENGOT)
Foundation Medicine
Open or close this module Oversight
U.S. FDA-regulated Drug: Yes
U.S. FDA-regulated Device: No
Data Monitoring: Yes
Open or close this module Study Description
Brief Summary: This is a Phase 3, randomized, multinational, double-blind, dual placebo-controlled, 4-arm study evaluating rucaparib and nivolumab as maintenance treatment following response to front-line treatment in newly diagnosed ovarian cancer patients. Response to treatment will be analyzed based on homologous recombination (HR) status of tumor samples.
Detailed Description:
Open or close this module Conditions
Conditions: Epithelial Ovarian Cancer
Primary Peritoneal
Fallopian Tube Cancer
Newly Diagnosed
FIGO Stage III-IV
Partial Response
Complete Response
Keywords: PARP inhibitor
PARPi
HRD
ATHENA
homologous recombination
DNA repair
LOH
DNA defect
DNA anomaly
Rucaparib
Nivolumab
PD-1
Immuno-
oncology
Tumor
mutational
burden
BRCA
First-line
Primary Therapy
Primary Treatment
Open or close this module Study Design
Study Type: Interventional
Primary Purpose: Treatment
Study Phase: Phase 3
Interventional Study Model: Parallel Assignment
Number of Arms: 4
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Allocation: Randomized
Enrollment: 1000 [Anticipated]
Open or close this module Arms and Interventions
Arms Assigned Interventions
Experimental: Arm A
oral rucaparib + intravenous (IV) nivolumab
 Drug: Rucaparib
Oral rucaparib will be administered twice daily
Other Names:
  • Rubraca
  • CO-338
Drug: Nivolumab
IV nivolumab will be administered once every 4 weeks
Other Names:
  • Opdivo
  • BMS-936558
Experimental: Arm B
oral rucaparib+IV placebo
 Drug: Rucaparib
Oral rucaparib will be administered twice daily
Other Names:
  • Rubraca
  • CO-338
Drug: Placebo IV Infusion
IV placebo will be administered once every 4 weeks
Experimental: Arm C
oral placebo+ IV nivolumab
 Drug: Nivolumab
IV nivolumab will be administered once every 4 weeks
Other Names:
  • Opdivo
  • BMS-936558
Drug: Placebo Oral Tablet
Placebo tablets will be administered twice daily
Placebo Comparator: Arm D
Oral placebo + IV placebo
 Drug: Placebo Oral Tablet
Placebo tablets will be administered twice daily
Drug: Placebo IV Infusion
IV placebo will be administered once every 4 weeks
Open or close this module Outcome Measures
Primary Outcome Measures:
1. Investigator assessed Progression-free survival (PFS)
[ Time Frame: From randomization until disease progression (up to approximately 7 years) ]
Secondary Outcome Measures:
1. Blinded independent central review (BICR) PFS
[ Time Frame: Every ~12 weeks after the start of combination treatment for ~3 years, then every ~24 weeks thereafter until disease progression. Study data collection expected to last for ~7 years ]
2. Overall Survival (OS)
[ Time Frame: From enrollment to primary study completion of study (up to approximately 10 years) ]
3. Objective response rate (ORR)
[ Time Frame: For patients with measurable disease, every ~12 weeks after the start of combination treatment for ~3 years, then every ~24 weeks thereafter until disease progression. Study data collection expected to last for ~7 years ]
4. Duration of response (DOR)
[ Time Frame: For patients with measurable disease, every ~12 weeks after the start of combination treatment for ~3 years, then every ~24 weeks thereafter until disease progression. Study data collection expected to last for ~7 years ]
5. Number of participants with treatment-emergent Adverse Events (AEs) as assessed by CTCAE v4 (or higher) as a measure of safety and tolerability
[ Time Frame: Collected from the time patient receives first dose of study drug until post treatment safety follow-up period (up to approximately 10 years) ]
6. Number of participants with serious AEs as a measure of safety and tolerability
[ Time Frame: Collected from the time patient receives first dose of study drug until post treatment safety follow-up period (up to approximately 10 years) ]
7. Number of participants with laboratory abnormalities as a measure of safety and tolerability
[ Time Frame: Collected from the time patient receives first dose of study drug until post treatment safety follow-up period (up to approximately 10 years) ]
Open or close this module Eligibility
Minimum Age: 18 Years
Maximum Age:
Sex: Female
Gender Based:
Accepts Healthy Volunteers: No
Criteria:

Inclusion Criteria:

  • Newly diagnosed advanced (FIGO stage III-IV) epithelial ovarian, fallopian tube, or primary peritoneal cancer.
  • Completed cytoreductive surgery, including at least a bilateral salpingo-oophorectomy and partial omentectomy, either prior to chemotherapy (primary surgery) or following neoadjuvant chemotherapy (interval debulking)
  • Completed first-line platinum-based chemotherapy and surgery with a response, in the opinion of the Investigator
  • Sufficient tumor tissue for planned analysis
  • ECOG performance status of 0 or 1
  • Patients must be 20 years of age to consent in Japan, Taiwan and South Korea; in all other participating countries patients must be 18 years of age to consent

Exclusion Criteria:

  • Pure sarcomas or borderline tumors or mucinous tumors
  • Active second malignancy
  • Known central nervous system brain metastases
  • Any prior treatment for ovarian cancer, other than the first-line platinum regimen
  • Evidence of interstitial lung disease or active pneumonitis
  • Active, known or suspected autoimmune disease
  • Condition requiring active systemic treatment with either corticosteroids (>10 mg daily prednisone equivalent) or other immunosuppressive medications
Open or close this module Contacts/Locations
Locations: United States, Arizona
Arizona Oncology Associates, PC - HAL
Phoenix, Arizona, United States, 85016
Arizona Oncology Associates, PC - HOPE
Tucson, Arizona, United States, 85711
The University of Arizona Cancer Center
Tucson, Arizona, United States, 85724
United States, California
John Muir Clinical Research Center
Concord, California, United States, 94520
UCLA Women's Health Clinical Research Unit
Los Angeles, California, United States, 90095
Kaiser Permanente Northern California
San Francisco, California, United States, 94589
United States, Colorado
University of Colorado Cancer Center
Aurora, Colorado, United States, 80045
Rocky Mountain Cancer Centers
Lakewood, Colorado, United States, 80228
United States, Connecticut
Yale University
New Haven, Connecticut, United States, 06520
United States, Florida
Florida Gynecologic Oncology
Fort Myers, Florida, United States, 33905
MD Anderson Cancer Center-Baptist
Jacksonville, Florida, United States, 32207
Baptist Health Medical Group Oncology, LLC
Miami, Florida, United States, 33176
Florida Hospital
Orlando, Florida, United States, 32804
United States, Georgia
Northside Hospital
Atlanta, Georgia, United States, 30342
Augusta University
Augusta, Georgia, United States, 30912
United States, Illinois
Rush University Medical Center
Chicago, Illinois, United States, 60612
Dr. Sudarshan K. Sharma, Ltd - Gynecologic Oncology
Hinsdale, Illinois, United States, 60521
Van le
Springfield, Illinois, United States, 62769
United States, Indiana
Community Health Network
Indianapolis, Indiana, United States, 46250
United States, Iowa
University of Iowa Hospitals
Iowa City, Iowa, United States, 52242
United States, Kansas
University of Kansas Cancer Center
Westwood, Kansas, United States, 66205
United States, Kentucky
University of Kentucky
Lexington, Kentucky, United States, 40536
Norton Cancer Institute
Louisville, Kentucky, United States, 40241
United States, Louisiana
Ochsner Medical Center
New Orleans, Louisiana, United States, 70121
United States, Maine
Maine Medical Center
Scarborough, Maine, United States, 04074
United States, Maryland
SKCCC at Johns Hopkins
Baltimore, Maryland, United States, 21287
United States, Massachusetts
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114
United States, Michigan
Karmanos Cancer Institute
Detroit, Michigan, United States, 48201
United States, Minnesota
Metro Minnesota Community Oncology Research Consortium
Saint Louis Park, Minnesota, United States, 55416
United States, Missouri
Washington University School of Medicine
Saint Louis, Missouri, United States, 63110
United States, Nevada
Women's Cancer Center of Nevada
Las Vegas, Nevada, United States, 89169
United States, New Jersey
MD Anderson Cancer Center at Cooper
Camden, New Jersey, United States, 08103
Summit Medical Group
Florham Park, New Jersey, United States, 07932
United States, New York
Women's Cancer Care Associates
Albany, New York, United States, 12008
Broome Oncology, LLC
Johnson City, New York, United States, 13790
Northwell Health Monter Cancer Center
Lake Success, New York, United States, 11042
New York University Medical Center
New York, New York, United States, 10016
United States, North Carolina
University of North Carolina
Chapel Hill, North Carolina, United States, 27707
United States, Ohio
University of Cincinnati
Cincinnati, Ohio, United States, 45221
Oncology Hematology Care, Inc
Cincinnati, Ohio, United States, 45242
Cleveland Clinic
Cleveland, Ohio, United States, 44106
The Ohio State University
Columbus, Ohio, United States, 43210
MD Anderson Cancer Center - Ohio Health
Columbus, Ohio, United States, 44907
United States, Oklahoma
University of Oklahoma Health Science Center
Oklahoma City, Oklahoma, United States, 73104
Oklahoma Cancer Specialists and Research Institute
Tulsa, Oklahoma, United States, 74146
United States, Oregon
Oncology Associates of Oregon, P.C.
Eugene, Oregon, United States, 97401
LMG Gynecologic Oncology
Portland, Oregon, United States, 97210
Northwest Cancer Specialists, P.C.
Portland, Oregon, United States, 97225
United States, Pennsylvania
University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104
Thomas Jefferson University
Philadelphia, Pennsylvania, United States, 19107
UPMC Magee-Womens Hospital
Pittsburgh, Pennsylvania, United States, 15213
Abington Memorial Hospital
Willow Grove, Pennsylvania, United States, 19090
United States, South Dakota
Avera Gynecologic Oncology
Sioux Falls, South Dakota, United States, 57105
United States, Texas
Texas Oncology - Austin Central
Austin, Texas, United States, 78731
Texas Oncology - Bedford
Bedford, Texas, United States, 76022
Texas Oncology - Dallas Presbyterian Hospital
Dallas, Texas, United States, 75231
Texas Oncology - Fort Worth
Fort Worth, Texas, United States, 76104
Memorial Hermann
Houston, Texas, United States, 77030
University of Texas MD Anderson Cancer Center
Houston, Texas, United States, 77030
Texas Oncology - San Antonio Medical Center
San Antonio, Texas, United States, 78240
Texas Oncology - The Woodlands, Gynecologic Oncology
The Woodlands, Texas, United States, 77380
United States, Utah
Huntsman Cancer Institute
Salt Lake City, Utah, United States, 84112
United States, Virginia
Virginia Oncology Associates
Norfolk, Virginia, United States, 23502
United States, Wisconsin
Froedtert and Medical College of Wisconsin
Milwaukee, Wisconsin, United States, 53226
Australia, New South Wales
Newcastle Private Hospital
New Lambton Heights, New South Wales, Australia, 2145
Northern Cancer Institute St Leonards
Saint Leonards, New South Wales, Australia, 2065
Prince of Wales Hospital
Sydney, New South Wales, Australia, 2031
Westmead Hospital
Westmead, New South Wales, Australia, 2145
Australia, Queensland
Royal Brisbane and Women's Hospital
Brisbane, Queensland, Australia, 4020
Australia, South Australia
Brian Fricker Oncology Centre, Burnside Hospital
Toorak Gardens, South Australia, Australia, 5065
Australia, Victoria
Peter MacCallum Cancer Center
Melbourne, Victoria, Australia, 3000
Australia, Western Australia
St John of God Subiaco Hospital
Subiaco, Western Australia, Australia, 6005
Belgium
UZ Leven
Leuven, Belgium, 3000
Canada, Alberta
Alberta Health Services - University of Calgary
Calgary, Alberta, Canada, T2N 1N4
Alberta Health Services and The University of Alberta
Edmonton, Alberta, Canada, T6G 2B7
Canada, British Columbia
BC Cancer - Abbotsford
Abbotsford, British Columbia, Canada, V2S 0C2
BC Cancer - Kelowna
Kelowna, British Columbia, Canada, V1Y 5L3
BC Cancer - Surrey
Surrey, British Columbia, Canada, V3V 1Z2
Canada, Manitoba
CancerCare Manitoba
Winnipeg, Manitoba, Canada, R3E 0V9
Canada, Nova Scotia
Nsha-Qeii Hsc
Halifax, Nova Scotia, Canada, B3H 2Y9
Canada, Ontario
Juravinski Cancer Center
Hamilton, Ontario, Canada, LbV 5C2
London Health Sciences Center
London, Ontario, Canada, N6A 5W9
Ottawa Hospital Cancer Centre
Ottawa, Ontario, Canada, K1H 8L6
Canada, Quebec
Centre Hospitalier de l'Université de Montreal
Montréal, Quebec, Canada, H2X 0C2
McGill University Health Center
Montréal, Quebec, Canada, H4A 3J1
Centre Integre Universitaire de sante et de service sociaux de l'Estri-Centre hospitalier univeritaire de Sherbrooke
Sherbrooke, Quebec, Canada, J1H 5N4
Czechia
Masaryk Memorial Cancer Institute
Brno, Czechia, 65653
Department of Gynecology and Obstetrics, Oncogynecological center U hiversity Hospital Kralovske Vinohrady
Prague, Czechia
KOC KNTB a.s. Zlfn, Hvalfckovo nabrezf 600, 76001
Zlín, Czechia
Denmark
Aalborg University Hospital
Aalborg, Denmark, 9000
Odense University Hospital
Odense, Denmark, 5000
Finland
Kuopio University Hospital
Kuopio, Finland, 70210
Germany
Klinik für Frauenheilkunde und Geburtshilfe
Dessau, Germany
Universitaetsklinikum Duesseldorf / Klinik fur Frauenheilkunde & Geburtshilfe
Duesseldorf, Germany
Universitatsklinikum National Centrum for Tumor Disease (NCT)
Heidelberg, Germany
Universitätslinikum Mannheim, Frauenklinik
Mannheim, Germany
Kliniken Suedostbayern AG, Klinikum Traunstein
Traunstein, Germany
Greece
Alexandra Hospital
Athens, Greece, 11528
General Hospital of Patras
Patra, Greece, 26335
Euromedica General Clinic, B' Oncology Clinic
Thessaloniki, Greece, 5465
Greece, Athens
Attikon General University Hospital
Chaidari, Athens, Greece, 12462
University Hospital Attikon
Chaidari, Athens, Greece, 12462
Ireland
Cork University Hospital
Cork, Ireland, T12 DC4A
Bon Secours Hospital
Cork, Ireland
University Hospital Limerick
Limerick, Ireland, V94 F858
University Hospital Waterford
Waterford, Ireland, X91 ER8E
Israel
Shaare Zedek Medical Oncology
Jerusalem, Israel
Meir Medical Center
Kfar Saba, Israel, 4428164
Galilee Medical Center
Nahariya, Israel, 2210001
Sheba Medical Center
Ramat Gan, Israel, 5265601
Ziv Medical Center
Safed, Israel, 13100
Tel Aviv Sourasky Medical Center
Tel Aviv, Israel, 6423906
Italy
Centro di Riferimento Oncologico, CRO-IRCCS
Aviano, Italy, 33081
Candiolo Cancer Institute - IRCCS
Candiolo, Italy, 10060
Arnas Garibaldi
Catania, Italy, 95122
University G, D'Annunuzio-Chieti
Chieti, Italy
IRCCS Instituto Nazionale Tumori
Napoli, Italy, 80131
Azienda Ospedaliera Universitaria Policlinico Umberto I
Roma, Italy, 00161
Policlinico Agostino Gemelli
Roma, Italy, 00168
Ospedale S. Giovanni Calibita Fatebenefratelli
Roma, Italy, 00186
Ospedale San Bortolo
Vicenza, Italy, 36100
Japan
Saitama Cancer Center
Saitama, Japan, 362-0806
Kagawa Prefectural Central Hospital
Takamatsu, Japan
National Cancer Center Hospital
Tokyo, Japan, 104-0045
Japan, Amakubo
University of Tsukuba Hospital
Tsukuba, Amakubo, Japan
Japan, Chiba
National Cancer Center Hospital East
Kashiwa, Chiba, Japan, 277-8577
Japan, Fukuoka
Kurume University Hospital
Kurume, Fukuoka, Japan, 830-0011
Japan, Fukuura
Yokohama City University Hospital
Yokohama, Fukuura, Japan
Japan, Gunma
Gunma University Hospital
Maebashi, Gunma, Japan, 371-8511
Gunma Prefectural Cancer Center
Ota-shi, Gunma, Japan, 373-8550
Japan, Hiroshima
Hiroshima City Hiroshima Citizens Hospital
Naka, Hiroshima, Japan, 730-0844,
Japan, Hyogo
Hyogo Cancer Center
Akashi, Hyogo, Japan, 673-0021
Japan, Iwate
Iwate Medical University
Morioka, Iwate, Japan
Japan, Kanagawa
Nippon Medical School Musashikosugi Hospital
Kawasaki-shi, Kanagawa, Japan, 211-8533
Kanagawa Cancer Center
Yokohama, Kanagawa, Japan, 241-8515
Japan, Namiki
National Defense Medical College Hospital
Tokorozawa, Namiki, Japan
Japan, Osaka
Osaka International Cancer Institute
Chuo, Osaka, Japan, 541-8567
Kindai University Hospital
Ōsaka-sayama, Osaka, Japan, 589-8511
Japan, Saitama
Saitama Medical University International Medical Center
Hidaka, Saitama, Japan, 350-1298
Japan, Shinanomachi
Keio University Hospital
Shinjuku-Ku, Shinanomachi, Japan
Japan, Tokyo
The Cancer Institute Hospital of JFCR
Koto-Ku, Tokyo, Japan
Korea, Republic of
SoonChunHyang Univeristy Cheonan Hosptial
Cheonan, Korea, Republic of
Korea Cancer Center Hospital
Seoul, Korea, Republic of, 01812
Seoul National University Hospital
Seoul, Korea, Republic of, 03080
Severance Hospital,Yonsei University Health System
Seoul, Korea, Republic of, 03722
Konkuk University Medical Center
Seoul, Korea, Republic of, 05030
Asan Medical Center
Seoul, Korea, Republic of, 05505
Samsung Medical Center
Seoul, Korea, Republic of, 06351
Korea University Guro Hospital
Seoul, Korea, Republic of
Ajou University Hospital
Suwon-si, Korea, Republic of
Korea, Republic of, Gyeonggi-do
National Cancer Center
Goyang-si, Gyeonggi-do, Korea, Republic of, 10408
CHA Bundang Medical Center
Seongnam, Gyeonggi-do, Korea, Republic of, 13496
Seoul National University Bundang Hospital
Seongnam-si, Gyeonggi-do, Korea, Republic of, 13620
Korea, Republic of, Seoul
Gachon University Gil Medical Center
Incheon, Seoul, Korea, Republic of, 21565
New Zealand
Auckland City Hospital
Auckland, New Zealand, 1023
Christchurch Hospital
Christchurch, New Zealand, 8011
Waikato Hospital
Hamilton, New Zealand, 3204
Palmerston North Hospital
Palmerston North, New Zealand, 4442
Tauranga Hospital
Tauranga, New Zealand, 3112
Poland
Bialostockie Centrum Onkologii Oddzial Onkologii Ginekologicznej
Bialystok, Poland, 20-081
University Hospital of Bialystok
Białystok, Poland
Szpitale Pomorskie sp zoo
Gdynia, Poland, 81-519
Medical University of Lublin
Lublin, Poland, 20-081
Wielkopolskie Centrum Onkologii
Poznań, Poland, 61-866
Pomeranian Medical University
Szczecin, Poland
Poland, Kondratowicza
Chair & department of Obsterics, Gynaecology and Oncology (previous site)
Warsaw, Kondratowicza, Poland
Romania
Oncopremium Team
Baia Mare, Romania
SC Quantum Medical Center SRL
Bucuresti, Romania
Instiute of Oncology - Medical Oncology
Cluj-Napoca, Romania
Centrul de Oncologie Sf.Nectarie
Craiova, Romania, 200347
S.C Oncolab S.R.L
Craiova, Romania
Institutul Regional de Oncologie Iasi
Iaşi, Romania, 700489
Spital Municipal Ploiesti
Ploieşti, Romania
Spitalul Judetean de Urgenta "Sfantul Ioan cel Nou" Suceava
Suceava, Romania, 720237
ONCOMED Timisoara
Timişoara, Romania, 300239
Romania, Jud. Bihor
Spitalul Clinic Municipal "Dr. Gavril Curteanu"
Oradea, Jud. Bihor, Romania, 410469
Romania, Jud. Cluj
S.C. Medisprof S.R.L.
Cluj-Napoca, Jud. Cluj, Romania, 400641
Russian Federation
Arkhangelsk Clinical Oncological Dispensary
Arkhangel'sk, Russian Federation, 163045
BHI of Omsk Region Clinical Oncology Dispensary
Omsk, Russian Federation, 644013
Orenburg Regional Clinical Oncological Dispensary
Orenburg, Russian Federation
SBHI Saint Petersburg Research Center specialized types of medical care (Oncology)
Pesochnyy, Russian Federation, 197758
SBHI SR Pyatigorsk Interdistrict Oncology Dispensary
Pyatigorsk, Russian Federation, 357502
Limited Liability Company MedPomosch
Saint Petersburg, Russian Federation, 194356
FSBEI HE I.P. Pavlov SPbSMU MoH Russia
Saint Petersburg, Russian Federation, 197022
Saint-Petersburg State Budget Institution of Healthcare City Clinical Oncology Dispensary
Saint Petersburg, Russian Federation, 198255
1st Medical University
Saint Petersburg, Russian Federation
Federa; State Budgetary Educational Institution of Higher Education National Research Ogarev Mordovia State University
Saransk, Russian Federation, 430032
State Medical Institution "Oncology Center #2" under the Krasnodar Region Healthcare Department
Sotchi, Russian Federation, 354057
Singapore
National University Hospital
Singapore, Singapore, 119082
National Cancer Center Singapore
Singapore, Singapore
Spain
Vall d'Hebron Institute of Oncology
Barcelona, Spain, 08035
Hospital de la Santa Creu i Sant Pau
Barcelona, Spain, 08041
Hospital Universitario Basurto
Bilbao, Spain, 48013
Consorcio Hospitalario Provincial Castellon
Castillón, Spain, 12002
Hospital Virgen de la Arrixaca
El Palmar, Spain, 30120
Hospital de Jerez
Jerez de la Frontera, Spain, 11407
Hospital Universitario Puerta de Hierro - Majadahonda
Madrid, Spain, 28222
Hospital Universitario Central de Asturias
Oviedo, Spain, 33011
Hospital Son Llatzer
Palma De Mallorca, Spain, 07198
Hospital Nuestra Señora de Valme
Sevilla, Spain, 41014
Sweden
Onkologiska Kliniken
Linköping, Sweden
Onkologiska Kliniken
Lund, Sweden
Karolinska Universitetssjukhuset
Stockholm, Sweden
Taiwan
Hualien Tzu Chi Hospital
Hualien City, Taiwan
Kaohsiung Veterans General Hospital
Kaohsiung, Taiwan, 81362
Far Eastern Memorial Hospital
New Taipei City, Taiwan, 22060
Taichung Veterans General Hospital
Taichung, Taiwan, 40705
China Medical University Hospital
Taichung, Taiwan
Chi Mei Hospital, Liouying (CMHLY)
Tainan, Taiwan
Chi Mei Medical Center (CMMC)
Tainan, Taiwan
National Taiwan University Hospital
Taipei, Taiwan, 10048
Mackay Memorial Hospital
Taipei, Taiwan, 10449
Taipei Veterans General Hospital
Taipei, Taiwan, 11217
Tri-Service General Hospital
Taipei, Taiwan, 11490
Taipei Medical Univeristy Hopsital
Taipei, Taiwan
Chang Gung Medical Foundation- Linkou Branch
Taoyuan, Taiwan, 33305
Turkey
Dr. Abdurrahman Yurtaslan Ankara Women's Health Education and Research Hospital
Ankara, Turkey
Istanbul University-cerrahpasa, Cerrahpasa School of Medicine
Istanbul, Turkey
Koc University School of Medicine, Koc University Hospital
Istanbul, Turkey
Celal Bayar University Faculty of Medicine
Manisa, Turkey, 45030
Baskent University Hospital
Yuregir, Turkey
United Kingdom
Royal Sussex County Hospital
Brighton, United Kingdom, BN2 3EH
Bristol Cancer Institute Medical Oncology
Bristol, United Kingdom, BS2 8HW
Addenbrookes Hospital
Cambridge, United Kingdom, CB2 0QQ
Western General Hospital
Edinburgh, United Kingdom, EH4 2XU
University Hospitals of Morecambe Bay NHS Foundation Trust
Lancaster, United Kingdom, LA1 4RP
St. James University Hospital
Leeds, United Kingdom, LS9 7TF
Barts and the London NHS Trust
London, United Kingdom, EC1A 7BE
University of College London Hospital
London, United Kingdom, NW1 2PG
Guy's & St Thomas' NHS Foundation Trust (Guy's Cancer Centre)
London, United Kingdom, SE1 9RT
The Royal Marsden NHS Foundation Trust
London, United Kingdom, SW3 6JJ
Imperial College London
London, United Kingdom, W12 0HS
The James Cook University Hospital
Middlesbrough, United Kingdom, TS4 3BW
Poole Hospital NHS Foundation Trust
Poole, United Kingdom, BH15 2JB
South West Wales Cancer Centre - Singleton Hospital
Swansea, United Kingdom, SA2 8QA
Musgrove Park Hospital
Taunton, United Kingdom, TA1 5DA
United Kingdom, Kent
East Kent Hospitals University NHS Foundation trust Medical Oncology
Canterbury, Kent, United Kingdom, CT1 3NG
United Kingdom, Northampton
Northampton General Hospital
Cliftonville, Northampton, United Kingdom, NN1 5BD
Open or close this module IPDSharing
Plan to Share IPD:
Open or close this module References
Links:
Available IPD/Information:
Scroll up to access the controls Scroll to the Study top
U.S. National Library of Medicine | U.S. National Institutes of Health | U.S. Department of Health & Human Services